Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PULSAR: High Dose Aflibercept in nAMD
NCT04423718Phase 3Completed
- Sponsor
- Bayer
- Start
- Aug 2020
- Primary completion
- Jul 2022
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 27
01
Overview
A Phase 3 trial of aflibercept in neovascular age-related macular degeneration (NVAMD), sponsored by Bayer. Started Aug 2020; status: completed.
02
Drugs
aflibercept
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT04423718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04423718.